Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203
- 9 February 2021
- journal article
- letter
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 62 (7), 1-7
- https://doi.org/10.1080/10428194.2021.1881512
Abstract
No abstract availableFunding Information
- National Cancer Institute
- National Institutes of Health (U01-CA180819, U01-CA180888)
This publication has 10 references indexed in Scilit:
- Selection of initial therapy for newly-diagnosed adult acute myeloid leukemia: Limitations of predictive modelsBlood Reviews, 2020
- Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid LeukemiaJCO Oncology Practice, 2020
- Therapeutic Choice in Older Patients with Acute Myeloid Leukemia: A Matter of FitnessCancers, 2020
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- SWOG S1203: A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy Versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)Blood, 2016
- Management of older or unfit patients with acute myeloid leukemiaLeukemia, 2014
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemiaBlood, 2013
- The development and validation of two prediction models to identify employees at risk of high sickness absenceEuropean Journal of Public Health, 2012
- Quantitative analysis of the color change after iodine staining for diagnosing esophageal high-grade intraepithelial neoplasia and invasive cancerGastrointestinal Endoscopy, 2009
- Can Routine Laboratory Tests Discriminate between Severe Acute Respiratory Syndrome and Other Causes of Community‐Acquired Pneumonia?Clinical Infectious Diseases, 2005